Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration to begin clinical trials for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24), which is designed to protect individuals aged six weeks and older against diseases caused by 24 pneumococcal serotypes. The candidate, which uses covalent conjugation and dual carrier technology and has completed key production and formulation development steps, would be the first 24-valent pneumococcal conjugate vaccine on the global market if successfully developed, potentially strengthening CanSino’s competitive positioning in the high-value pneumococcal vaccine segment and signaling an important pipeline milestone for investors and industry stakeholders.
The most recent analyst rating on (HK:6185) stock is a Hold with a HK$35.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company focused on the research, development and production of innovative vaccines. Its portfolio and pipeline target infectious diseases with significant public health impact, positioning the company within the global vaccine and immunization industry.
Average Trading Volume: 736,819
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.64B
For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.